Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H28BrN5O5 |
| Molecular Weight | 522.392 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1C(=O)N(CCO)C2=C(N(CC3=CC(Br)=C(OC)C=C3)C(N[C@@H]4CCC[C@H]4O)=N2)C1=O
InChI
InChIKey=RCJYGWGQCPDYSL-HZPDHXFCSA-N
InChI=1S/C22H28BrN5O5/c1-3-26-20(31)18-19(27(9-10-29)22(26)32)25-21(24-15-5-4-6-16(15)30)28(18)12-13-7-8-17(33-2)14(23)11-13/h7-8,11,15-16,29-30H,3-6,9-10,12H2,1-2H3,(H,24,25)/t15-,16-/m1/s1
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.pharmacodia.com/yaodu/html/v1/chemicals/4b58db5ec33af76c6d9b968cf2c633b1.html | http://adisinsight.springer.com/drugs/800018967
Curator's Comment: description was created based on several sources, including:
https://www.pharmacodia.com/yaodu/html/v1/chemicals/4b58db5ec33af76c6d9b968cf2c633b1.html | http://adisinsight.springer.com/drugs/800018967
Schering published xanthine PDE5 inhibitors with amino substituents in the imidazole 2-position, such as Dasantafil. Dasantafil, also known as SCH-446132, is a PDE5A inhibitor potentially for the treatment of erectile dysfunction. It had been in phase II clinical trials but there is no report for this compound recently.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2127
Created by
admin on Sat Dec 16 16:47:24 GMT 2023 , Edited by admin on Sat Dec 16 16:47:24 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2107326
Created by
admin on Sat Dec 16 16:47:23 GMT 2023 , Edited by admin on Sat Dec 16 16:47:23 GMT 2023
|
PRIMARY | |||
|
9871410
Created by
admin on Sat Dec 16 16:47:24 GMT 2023 , Edited by admin on Sat Dec 16 16:47:24 GMT 2023
|
PRIMARY | |||
|
300000034103
Created by
admin on Sat Dec 16 16:47:24 GMT 2023 , Edited by admin on Sat Dec 16 16:47:24 GMT 2023
|
PRIMARY | |||
|
C76888
Created by
admin on Sat Dec 16 16:47:24 GMT 2023 , Edited by admin on Sat Dec 16 16:47:24 GMT 2023
|
PRIMARY | |||
|
8485
Created by
admin on Sat Dec 16 16:47:23 GMT 2023 , Edited by admin on Sat Dec 16 16:47:23 GMT 2023
|
PRIMARY | |||
|
569351-91-3
Created by
admin on Sat Dec 16 16:47:23 GMT 2023 , Edited by admin on Sat Dec 16 16:47:23 GMT 2023
|
PRIMARY | |||
|
PP-55
Created by
admin on Sat Dec 16 16:47:24 GMT 2023 , Edited by admin on Sat Dec 16 16:47:24 GMT 2023
|
PRIMARY | |||
|
48P711MI2G
Created by
admin on Sat Dec 16 16:47:23 GMT 2023 , Edited by admin on Sat Dec 16 16:47:23 GMT 2023
|
PRIMARY | |||
|
DTXSID30205480
Created by
admin on Sat Dec 16 16:47:23 GMT 2023 , Edited by admin on Sat Dec 16 16:47:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
